InvestSMART

Starpharma Holdings Limited (ASX: SPL) - Announcements

Current share price for SPL : $0.790 0.005 (0.63%)+

ASX company news and announcements for Starpharma Holdings Limited (SPL) are delayed by 20 minutes from the time of their release between 7.30am and 7.30pm EDT and are in PDF format. All Starpharma Holdings Limited (SPL) ASX announcements deemed to be price sensitive will be highlighted with . If you are looking for ASX announcements for companies other than Starpharma Holdings Limited (SPL), please use our Company Announcements tool to search across all ASX-listed companies.

Latest company announcements for Starpharma Holdings Limited (SPL)

Search all Announcements
Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
$333 Starpharma partners with UQ to advance DEP radio pipeline 26 Jul 2023 9:30AM $0.360 $0.790 risen by 119.44%
$333 DEP HER2-radiodiagnostic shows imaging benefits 21 Jul 2023 9:02AM $0.370 $0.790 risen by 113.51%
$333 Notification of cessation of securities - SPL 7 Jul 2023 2:13PM $0.350 $0.790 risen by 125.71%
$333 Clinical Trial Update 27 Jun 2023 9:57AM $0.325 $0.790 risen by 143.08%
$333 Life Sciences Investor Forum Presentation 23 Jun 2023 10:42AM $0.355 $0.790 risen by 122.54%
$333 Starpharma to present at Life Sciences Investor Forum 22 Jun 2023 12:48PM $0.350 $0.790 risen by 125.71%
$333 AZD0466 Clinical Data Presented by AstraZeneca EHA Congress 14 Jun 2023 10:36AM $0.380 $0.790 risen by 107.89%
$333 Starpharma CEO to retire in 2024 9 Jun 2023 9:32AM $0.370 $0.790 risen by 113.51%
$333 VIRALEZE Nasal Spray Approved in Malaysia 5 Jun 2023 9:45AM $0.390 $0.790 risen by 102.56%
$333 Application for quotation of securities - SPL 5 May 2023 5:04PM $0.450 $0.790 risen by 75.56%
$333 Quarterly Activities/Appendix 4C Cash Flow Report 28 Apr 2023 9:31AM $0.480 $0.790 risen by 64.58%
$333 HER2-targeted DEP SN38 ADC outperforms in HER2 cancer model 26 Apr 2023 10:15AM $0.490 $0.790 risen by 61.22%
$333 AZD0466 active in small cell lung cancer patient models 20 Apr 2023 9:16AM $0.500 $0.790 risen by 58%
$333 DEP cabazitaxel Ph 2 trial completes enrolment & treatment 17 Apr 2023 10:21AM $0.495 $0.790 risen by 59.60%
$333 Commencement of CFO and Company Secretary 3 Apr 2023 9:04AM $0.460 $0.790 risen by 71.74%
$333 Starpharma presents at ASX Small and Mid-Cap Conference 22 Mar 2023 10:22AM $0.470 $0.790 risen by 68.09%
$333 Application for quotation of securities - SPL 17 Mar 2023 4:33PM $0.525 $0.790 risen by 50.48%
$333 CFO and Company Secretary Appointment 3 Mar 2023 9:38AM $0.515 $0.790 risen by 53.40%
$333 Interim Report and Half-Year Financial Results 28 Feb 2023 9:29AM $0.565 $0.790 risen by 39.82%
$333 Dr Russell Basser appointed as director and Appendix 3X 20 Feb 2023 2:16PM $0.560 $0.790 risen by 41.07%
$333 Change in substantial holding 10 Feb 2023 5:15PM $0.560 $0.790 risen by 41.07%
$333 Change in substantial holding 10 Feb 2023 8:22AM $0.555 $0.790 risen by 42.34%
$333 Application for quotation of securities - SPL 1 Feb 2023 2:31PM $0.570 $0.790 risen by 38.60%
$333 Appointment of Company Secretary 1 Feb 2023 9:35AM $0.565 $0.790 risen by 39.82%
$333 Dr Russell Basser appointed as non-executive director 31 Jan 2023 11:18AM $0.610 $0.790 risen by 29.51%

176 - 200 of 866 results

Page 8 of 35

  • + Company announcements and prices are delayed by least 20 minutes. Prices are indicative only.

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.